Topical Tacrolimus for Vernal Keratoconjunctivitis: A Systematic Review-Reference-Cited by-同舟云学术

Topical Tacrolimus for Vernal Keratoconjunctivitis: A Systematic Review

Published:2023-03-15 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Chandra Michael¹,Angelina Monica¹

Affiliation:

1. Atma Jaya Catholic University

Abstract

Abstract Purpose Vernal keratoconjunctivitis (VKC) is a severe ocular inflammatory disease that requires potent anti-inflammatory drugs as a reliever. Despite the unpopularity, tacrolimus could admirably control inflammations. However, studies regarding topical tacrolimus effectivity for VKC are still lacking. Methods We conduct a systematic review to evaluate the effect of topical tacrolimus for VKC. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist for this systematic review. Relevant articles were retrieved from Cochrane Library, PubMed, EBSCO Host, and ProQuest database. We specifically included publication in English. This study was registered with PROSPERO under the number CRD42022302291. Results A total of 7 studies were included, involving 232 participants, with a mean age of 10.6 ± 4.3 years. In general, topical tacrolimus reduced the total objective signs score (TOSS) as well as the total subjective symptoms score (TSSS). Adverse events reported from topical tacrolimus were insignificant. Conclusion The results of this systematic review suggest that topical tacrolimus could significantly reduce VKC signs and symptoms. Further randomized trials and analyses are required to provide more evidence regarding this intervention.

Publisher

Research Square Platform LLC

Reference19 articles.

1. Alemayehu AM, Yibekal BT, Fekadu SA. Prevalence of vernal keratoconjunctivitis and its associated factors among children in Gambella town, southwest Ethiopia, June 2018. PLoS One [Internet]. 2019 1 April [cited 2023 2 March];14(4). Available from: https://pubmed.ncbi.nlm.nih.gov/30998721/

2. Vernal keratoconjunctivitis: An update;Smedt S;British Journal of Ophthalmology,2013

3. Ghiglioni DG, Zicari AM, Parisi GF, Marchese G, Indolfi C, Diaferio L, et al. Vernal keratoconjunctivitis: An update. Eur J Ophthalmol [Internet]. 2021 Nov 1 [cited 2023 Mar 2];31(6):2828–42. Available from: https://pubmed.ncbi.nlm.nih.gov/34058899/

4. Hazarika AK, Singh PK. Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. J Nat Sci Biol Med [Internet]. 2015 1 August [cited 2023 2 March];6(Suppl 1):S10. Available from: /pmc/articles/PMC4630738/

5. Al-Amri AM, Mirza AG, Al-Hakami AM. Tacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis. Middle East Afr J Ophthalmol [Internet]. 2016 Jan 1 [cited 2023 Mar 2];23(1):135–8. Available from: https://pubmed.ncbi.nlm.nih.gov/26957853/